Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012

Jacques Ferlay, Eva Steliarova‐Foucher, Joannie Lortet‐Tieulent et al. · European Journal of Cancer · 2013 · 5.2K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Modeling Valuations for EuroQol Health States

Paul Dolan · Medical Care · 1997 · 4.6K citations

Pharmacy, Health Policy, Health Assessment +16

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 2.3K citations

Medicine, Oncology, Pharmacotherapy +15

Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +15

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Hans‐Joachim Schmoll, Eric Van Cutsem, Alexander Stein et al. · Annals of Oncology · 2012 · 1.5K citations · Full text

Medicine, Oncology, Surgery +17